Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of fostamatinib versus placebo in persistent/chronic immune thrombocytopenic purpura
NL-OMON42185Phase 3Active, not recruiting
- Sponsor
- Syneos Health
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Fostamatinib with Placebo (2 arms). Primary endpoint: Stable platelet response at week 24. Started Mar 2015; status: active, not recruiting.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON42185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42185.